Bluejay Diagnostics, Inc. 8-K

What Happened
On March 6, 2026, Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced a corporate and strategic update and furnished certain financial results for the year ended December 31, 2025 via a press release. The company filed this information in an 8‑K under Item 2.02 (Results of Operations and Financial Condition) and included the press release as Exhibit 99.1.

Key Details

• Press release dated March 6, 2026 was furnished with the 8‑K (Exhibit 99.1).
• The filing covers financial results "as of and for the year ended December 31, 2025."
• The 8‑K was filed with accession number 0001213900-26-024352 and includes the Inline XBRL cover page (Exhibit 104).

Why It Matters
This filing signals the company has provided year‑end financial information and a strategic outlook that could affect expectations for earnings, revenue trends, and operational priorities. Retail investors should read the March 6 press release and any accompanying SEC filings for the specific financial metrics and management commentary to assess impacts on near‑term performance and valuation.